Israel’s aMoon leads $110 million funding round in SOPHiA GENETICS
The new funding aims to boost the medtech company’s penetration in both the U.S. and Asian markets
Hagar Ravet | 10:25 04.10.2020
Israel-based life sciences venture capital firm aMoon led a $110 million series F financing round in Swiss Medtech company SOPHiA GENETICS, according to a company statement issued this weekend. Hitachi Ventures, the venture arm of Japan’s Hitachi Group co-led the round, which was also participated by Credit Suisse, Swisscom Ventures, Endeavour Vision, Generation Investment Management, and the Pictet group. SOPHiA GENETICS operates in the field of medical data and has established the world’s largest data-driven medicine community network based on its universal and collaborative AI platform. Its network supports healthcare professionals by translating complex medical data into valuable clinical insights. According to the company's statement, the SOPHiA platform is used by over 1,000 healthcare institutions and has analyzed 600,000 genomic profiles. The new funding aims to boost the company’s penetration in both the U.S. and Asian markets.